Author： Crandon Jared Nicolau David P
Publisher： Future Medicine
ISSN： 1746-0913
Source： Future Microbiology, Vol.3, Iss.3, 2008-06, pp. : 251-263
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Oritavancin is a lipoglycopeptide antibiotic with activity against aerobic and anaerobic Gram-positive bacteria. Oritavancin separates itself from other glycopeptides through its potent in vitro activity against resistant isolates of Staphylococcus aureus, Enterococcus spp. and Streptococcus spp. Oritavancin possesses a long half-life that should allow, at maximum, once-daily dosing. Currently, oritavancin has completed two Phase III trials and one Phase II trial for the treatment of complicated skin and skin structure infections, and two Phase II trials for the treatment of Gram-positive bacteremia. In all instances, oritavancin displayed favorable outcomes and was noninferior to comparator agents (vancomycin followed by oral cephalexin) when a comparison was made. Further studies are necessary to fully characterize dose and clinical role.
Related content
Access to resources
Recommend
By Antikainen Jenni Kuparinen Veera Lähteenmäki Kaarina Korhonen Timo K.
FEMS Immunology & Medical Microbiology, Vol. 51, Iss. 3, 2007-12 ,pp. :
By Čermák P. Kolář M. Látal T. Heinigeová B. Bartoníková N.
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 23, Iss. 10, 2004-10 ,pp. :
The biology of Gram-positive sortase enzymes
By Paterson G.K. Mitchell T.J.
Trends in Microbiology, Vol. 12, Iss. 2, 2004-02 ,pp. :